文献速递胸部肿瘤

晚期EGFR突变非小细胞肺癌中EGFR突变丰度的综合分析及其对EGFR酪氨酸激酶抑制剂疗效的影响

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.
PubMed 文献 · J Thorac Oncol · 2017-06-15

本研究采用优化扩增阻碍突变系统(ARMS+)定量检测201例晚期非小细胞肺癌(NSCLC)患者的EGFR突变丰度,通过训练组确定截断值并在验证组验证。结果显示EGFR激活突变丰度与EGFR酪氨酸激酶抑制剂(TKIs)客观缓解显著相关,19DEL和L858R的截断值分别为4.9%和9.5%,高丰度组中位无进展生存期显著长于低丰度组。EGFR T790M突变丰度可能对无进展生存期而非客观缓解率有不良影响。

要点

  • ARMS+可定量检测EGFR突变丰度,19DEL截断值4.9%,L858R截断值9.5%。
  • 高丰度组中位PFS显著长于低丰度组:19DEL 15.0 vs 2.0个月,L858R 12.3 vs 2.0个月。
  • 13例T790M突变患者中9例达部分缓解,其中7例为低丰度T790M。

核心结论

  • ARMS+检测的EGFR激活突变丰度与EGFR TKIs客观缓解显著相关。
  • EGFR T790M突变丰度可能对晚期EGFR突变NSCLC患者接受EGFR TKIs治疗的无进展生存期有不良影响,而非客观缓解率。

研究设计与样本

  • 研究纳入201例晚期NSCLC患者,采用优化扩增阻碍突变系统(ARMS+)定量评估EGFR突变丰度。
  • 通过受试者工作特征分析在训练组确定EGFR突变丰度截断值,并在验证组验证。

主要发现

  • ARMS+检测的EGFR激活突变丰度与EGFR TKIs客观缓解显著相关。
  • 19DEL丰度显著高于L858R,19DEL和L858R的截断值分别为4.9%和9.5%。
  • 训练组中高丰度组中位无进展生存期显著长于低丰度组:19DEL 15.0个月 vs 2.0个月(p < 0.001),L858R 12.3个月 vs 2.0个月(p < 0.001)。
  • 验证组观察到相似结果。
  • 13例携带T790M突变的患者中9例对EGFR TKIs达到部分缓解,其中7例(7/9)鉴定为低丰度T790M突变。

关键数值与推荐

  • 19DEL的丰度截断值为4.9%,L858R的丰度截断值为9.5%。
  • 训练组高丰度组 vs 低丰度组中位无进展生存期:19DEL 15.0个月 vs 2.0个月(p < 0.001),L858R 12.3个月 vs 2.0个月(p < 0.001)。
  • 13例T790M突变患者中9例达部分缓解,其中7例为低丰度T790M突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A qualitative detection method for EGFR mutations is not sufficient to guide precise targeted therapy in clinical practice. The aim of this study was to explore the relationship between the abundance of EGFR mutations and efficacy of EGFR tyrosine kinase inhibitors (TKIs). METHODS: We used the amplification refractory mutation system (ARMS) method optimized with competitive blockers and specific mutation quantitation (ARMS+) to quantitatively evaluate the abundance of EGFR mutations in 201 patients with advanced NSCLC. A cutoff value of the abundance of EGFR mutations was determined by receiver operating characteristic analysis in a training group and validated in a validation group. RESULTS: The abundance of EGFR activating mutation by ARMS+ was significantly associated with objective response to EGFR TKIs. The abundance of 19DEL was significantly higher than that of L858R, with cutoff values for 19DEL and L858R of 4.9% and 9.5%, respectively. The median progression-free survival in the high group was significantly longer than that in the low group (19DEL, 15.0 versus 2.0 months [p < 0.001] and L858R, 12.3 versus 2.0 months [p < 0.001]) in the training set. Similar results were also observed in the validation set. Nine of 13 patients harboring T790M mutation achieved a partial response to EGFR TKIs. Most (seven of nine) were identified to have a low abundance of T790M mutation. The abundance of EGFR mutations appeared to be more significantly associated with the copy number of EGFR mutations from circulating tumor DNA in 19DEL group. CONCLUSION: The abundance of EGFR activating mutation by ARMS+ was significantly associated with objective response to EGFR TKIs. The abundance of EGFRT790M mutation may have an adverse impact on progression-free survival rather than on objective response rate in patients with advanced EGFR-mutant NSCLC treated with EGFR TKIs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Li X, Cai W, Yang G, et al. Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. J Thorac Oncol. 2017. PMID: 28624467. doi:10.1016/j.jtho.2017.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。